Time filter

Source Type

Apeldoorn, Netherlands

Barentsz J.O.,Radboud UMC | Thoeny H.C.,University of Bern
Nature Reviews Urology | Year: 2015

Most metastatic lymph nodes in patients with prostate cancer go undetected by current imaging techniques and limited pelvic lymph node dissection (PLND), as they are small and located in difficult-to-reach areas. As the only current alternative is an extended PLND, the search for more accurate imaging techniques continues. © 2015 Macmillan Publishers Limited. All rights reserved. Source

Zajda J.,MOCONTI Sp.z O.o Urological Office | Farag F.,Radboud UMC | Farag F.,Sohag University
Advances in Urology | Year: 2013

Objective. To evaluate the efficacy and safety of the new injectable implant, Urolastic, in women with stress urinary incontinence (SUI) after 12-month followup. Materials and Methods. A prospective, cohort study included adult women with SUI. Patients were treated with Urolastic periurethral injections under local anaesthesia. The injection procedure was repeated after 6 weeks when indicated. Patients were evaluated for efficacy and safety parameters 6 weeks, 3 months, and 12 months after therapy. Results. Twenty women 56 (33-71) years old were included. Thirteen patients (65%) received one injection each (overall average of 2,1 mL); 7 patients (35%) received a second injection. Nineteen patients complete the 12-month followup. The mean Stamey incontinence grade significantly decreased from 1.9 at baseline to 0.4 at 12 months (visit IV) (P < 0.001). None of the patients were dry at baseline; 68% of them were dry at 12 months. The mean number of incontinence episodes significantly decreased from 6/day at baseline to 1.6/day at visit IV (P < 0.001). Reduction in pad weight went from 20.2 to 7.8 g at one year. The mean I-QoL score significantly increased from 51 at baseline to 76 at visit IV (P < 0.001). Six patients (30%) developed minor complications related to the injection procedure. Conclusions. Urolastic is effective and long-standing urethral bulking agent with moderate adverse events. © 2013 Janusz Zajda and Fawzy Farag. Source

Koop A.,Albert Schweitzer Hospital | Vroemen J.,Amphia Hospital | Schreinemakers J.,Radboud UMC
Annals of Tropical Medicine and Public Health | Year: 2016

A 45-year-old woman presented with a painful swelling of the right leg. Twenty years previously, she suffered from malaria and was treated with intramuscular injections of pure quinine. Over the years, she noticed two solid tumors at the site of the quinine injections. Because of the pain and discomfort, we decided to excise the tumor. No evidence exists indicating how to treat dystrophic calcifications after intramuscular injections. Our advice is to consider resection if the calcifications are present for many years and cause complaints. Source

Lam J.,Rice University | Lu S.,Rice University | Lee E.J.,Rice University | Trachtenberg J.E.,Rice University | And 8 more authors.
Osteoarthritis and Cartilage | Year: 2014

Objective: To investigate the ability of cell-laden bilayered hydrogels encapsulating chondrogenically and osteogenically (OS) pre-differentiated mesenchymal stem cells (MSCs) to effect osteochondral defect repair in a rabbit model. By varying the period of chondrogenic pre-differentiation from 7 (CG7) to 14 days (CG14), the effect of chondrogenic differentiation stage on osteochondral tissue repair was also investigated. Methods: Rabbit MSCs were subjected to either chondrogenic or osteogenic pre-differentiation, encapsulated within respective chondral/subchondral layers of a bilayered hydrogel construct, and then implanted into femoral condyle osteochondral defects. Rabbits were randomized into one of four groups (MSC/MSC, MSC/OS, CG7/OS, and CG14/OS; chondral/subchondral) and received two similar constructs bilaterally. Defects were evaluated after 12 weeks. Results: All groups exhibited similar overall neo-tissue filling. The delivery of OS cells when compared to undifferentiated MSCs in the subchondral construct layer resulted in improvements in neo-cartilage thickness and regularity. However, the addition of CG cells in the chondral layer, with OS cells in the subchondral layer, did not augment tissue repair as influenced by the latter when compared to thecontrol. Instead, CG7/OS implants resulted in more irregular neo-tissue surfaces when compared to MSC/OS implants. Notably, the delivery of CG7 cells, when compared to CG14 cells, with OS cells stimulated morphologically superior cartilage repair. However, neither osteogenic nor chondrogenic pre-differentiation affected detectable changes in subchondral tissue repair. Conclusions: Cartilage regeneration in osteochondral defects can be enhanced by MSCs that are chondrogenically and osteogenically pre-differentiated prior to implantation. Longer chondrogenic pre-differentiation periods, however, lead to diminished cartilage repair. © 2014 Osteoarthritis Research Society International. Source

Alghamdi H.S.,Radboud UMC | Alghamdi H.S.,King Saud University | Bosco R.,Radboud UMC | Both S.K.,Radboud UMC | And 4 more authors.
Biomaterials | Year: 2014

The prevalence of osteoporosis will increase within the next decades due to the aging world population, which can affect the bone healing response to dental and orthopedic implants. Consequently, local drug targeting of peri-implant bone has been proposed as a strategy for the enhancement of bone-implant integration in osteoporotic conditions. In the present study, an established in-vivo femoral condyle implantation model in osteoporotic and healthy bone is used to analyze the osteogenic capacity of titanium implants coated with bisphosphonate (BP)-loaded calcium phosphate nanoparticles (nCaP) under compromised medical conditions. After 4 weeks of implantation, peri-implant bone volume (%BV; by μCT) and bone area (%BA; by histomorphometry) were significantly increased within a distance of 500μm from implant surfaces functionalized with BP compared to control implants in osteoporotic and healthy conditions. Interestingly, the deposition of nCaP/BP coatings onto implant surfaces increased both peri-implant bone contact (%BIC) and volume (%BV) compared to the deposition of nCaP or BP coatings individually, in osteoporotic and healthy conditions. The results of real-time PCR revealed similar osteogenic gene expression levels to all implant surfaces at 4-weeks post-implantation. In conclusion, simultaneous targeting of bone formation (by nCaP) and bone resorption (by BP) using nCaP/BP surface coatings represents an effective strategy for synergistically improvement of bone-implant integration, especially in osteoporotic conditions. © 2014 Elsevier Ltd. Source

Discover hidden collaborations